CLINICAL TRIALS PROFILE FOR GALLIUM DOTATOC GA-68
✉ Email this page to a colleague
All Clinical Trials for Gallium Dotatoc Ga-68
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT01619865 ↗ | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors | Completed | Sue O'Dorisio | Phase 1/Phase 2 | 2012-02-21 | This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used to measure response to treatment. These studies will be obtained with the long term goal of submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and children. |
| NCT01619865 ↗ | Safety of 68Ga-DOTA-tyr3-Octreotide PET in Diagnosis of Solid Tumors | Completed | University of Iowa | Phase 1/Phase 2 | 2012-02-21 | This protocol is designed to test the efficacy of 68Ga-DOTATOC PET/CT in diagnosis, staging, and measurement of response to treatment in patients with somatostatin receptor positive tumors. Goals are to 1) compare this unique PET/CT scan with the current standard of care which is a combination of Octreoscan SPECT (single photon emission tomography) plus a high resolution, contrast enhanced CT; 2) Determine the sensitivity of 68Ga-DOTATOC PET/CT in diagnosis of patients with suspected somatostatin receptor positive tumor; and 3) For those patients who have had recent treatment (e.g., surgery, chemotherapy, targeted therapy such as anti-angiogenics, kinase inhibitors, peptide receptor radiotherapy), this scan will be used to measure response to treatment. These studies will be obtained with the long term goal of submitting a New Drug Application (NDA) for FDA approval of 68Ga-DOTATOC PET/CT in adults and children. |
| NCT02375464 ↗ | Gallium-68 DOTATOC for Management of Neuroendocrine Tumors | No longer available | Northwell Health | 2015-04-01 | Gallium-68 DOTATOC is a material used to find neuroendocrine tumors (NETs) using positron emission tomography (PET scan). The material has already been shown to be better than the currently available imaging agents. This study is designed to evaluate the clinical impact of PET CT scanning using this agent in the evaluation and management of patients with NETs. | |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Gallium Dotatoc Ga-68
Condition Name
Clinical Trial Locations for Gallium Dotatoc Ga-68
Trials by Country
Clinical Trial Progress for Gallium Dotatoc Ga-68
Clinical Trial Phase
Clinical Trial Sponsors for Gallium Dotatoc Ga-68
Sponsor Name
